{"transactions":[{"id":857667,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO, CSO, and Corp Secretary"}}],"security":"Class A Common Stock","published_at":"2026-03-05T23:07:56.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."}],"balance_after":2183005,"source":{"system":"sec-edgar","filing":"0001104659-26-024233","document":"tm268148-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465926024233/tm268148-2_4seq1.xml","form_type":"4"}},{"id":857666,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO, CSO, and Corp Secretary"}}],"security":"Class A Common Stock","published_at":"2026-03-05T23:07:56.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":862500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":866133,"source":{"system":"sec-edgar","filing":"0001104659-26-024233","document":"tm268148-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465926024233/tm268148-2_4seq1.xml","form_type":"4"}},{"id":1134665,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"officer":true,"officer_title":"Exec VP, CLO & Corp Secretary"}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:57:12.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."}],"balance_after":1316872,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1316872},"source":{"system":"sec-edgar","filing":"0001610717-25-000137","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000161071725000137/form4.xml","form_type":"4"}},{"id":1415023,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Stock Option","published_at":"2024-09-05T01:58:43.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":480631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":480631,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":480631},"source":{"system":"sec-edgar","filing":"0001104659-24-097066","document":"tm2423415-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924097066/tm2423415-7_4seq1.xml","form_type":"4"}},{"id":1415022,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:58:43.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":180110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an award of restricted stock units (\"RSUs\") in the amount of 81,428 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023."}],"balance_after":261538,"source":{"system":"sec-edgar","filing":"0001104659-24-097066","document":"tm2423415-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924097066/tm2423415-7_4seq1.xml","form_type":"4"}},{"id":1564475,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Stock Option","published_at":"2024-03-21T23:43:35.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":81300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":81300,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":81300},"source":{"system":"sec-edgar","filing":"0001104659-24-037433","document":"tm249503-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924037433/tm249503-1_4seq1.xml","form_type":"4"}},{"id":1823915,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":81428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":81428,"derivative":{"underlying":"Common Stock","underlying_shares":81428},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823914,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":106609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":106609,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":106609},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823913,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":12656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on October 20, 2021, which vests in four yearly installments from October 20, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on October 20, 2021, which vests in four yearly installments from October 20, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":12656,"derivative":{"exercise_price":10,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":12656},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823912,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":77647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from August 9, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from August 9, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":77647,"derivative":{"exercise_price":10,"expiration_date":"2031-08-23","underlying":"Common Stock","underlying_shares":77647},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}}]}